| 交易日 | 两融余额(元) | 余额变动(元) | | 变动幅度 | | --- | --- | --- | --- | --- | | 2025-10-31 | 443.10万 | | 14.59万 | 3.41% | | 2025-10-30 | 428.50万 | | 56.50万 | 15.19% | | 2025-10-29 | 372.00万 | | 74.78万 | 25.16% | | 2025-10-28 | 297.22万 | | 27.33万 | 10.13% | | 2025-10-27 | 269.89万 | | 16.85万 | 6.66% | 小知识 证券之星消息，10月31日，医疗ETF龙头（560260）融资买入52.97万元，融资偿还38.37万元，融资净 买入14.59万元，融资余额443.1万元，近3个交易日已连续净买入累计145.88万元。 | 交易日 | 融资净买入 (元) 融资余额 (元) | | 占流通市值比 | | --- | --- | --- | --- | | 2025-10-31 | 14.59万 | 443.10万 | | | 2025-10-3 ...

证券之星消息，10月30日，医疗ETF龙头（560260）融资买入150.37万元，融资偿还93.87万元，融资净 买入56.5万元，融资余额428.5万元，近3个交易日已连续净买入累计158.61万元。 | 交易日 | 两融余额(元) | 余额变动(元) | 变动幅度 | | --- | --- | --- | --- | | 2025-10-30 | 428.50万 | 56.50万 | 15.19% | | 2025-10-29 | 372.00万 | 74.78万 | 25.16% | | 2025-10-28 | 297.22万 | 27.33万 | 10.13% | | 2025-10-27 | 269.89万 | 16.85万 | 6.66% | | 2025-10-24 | 253.04万 | -4.91万 | -1.90% | 小知识 融资融券：目前，个人投资者参与融资融券主要需要具备2个条件：1、从事证券交易至少6个月；2、账 户资产满足前20个交易日日均资产50万。融资融券标的：上交所将主板标的股票数量由现有的800只扩 大到1000只，深交所将注册制股票以外的标的股票数量由现有的800 ...

Core Viewpoint - The Hong Kong stock market experienced a slight decline, but the innovative drug sector showed significant movement, with Innovent Biologics surging 17% in a single day, leading to a strong rebound in related ETFs [1] Group 1: Market Performance - The largest thematic ETF in the Hong Kong market, the Hong Kong Innovative Drug ETF (513120), was the most actively traded, with a turnover rate exceeding 38% and a transaction volume close to 40 billion yuan by 11:30 AM [1] - The surge in innovative drugs is attributed to multiple industry catalysts, enhancing market confidence [1] Group 2: Industry Catalysts - The China National Medical Products Administration issued 11 innovative drug approvals at the end of May, boosting expectations for commercialization among pharmaceutical companies [1] - High-quality research results from domestic innovative drugs were showcased at the American Society of Clinical Oncology (ASCO) and American College of Rheumatology (ACR) meetings, validating the value of leading pharmaceutical pipelines and business development capabilities [1] Group 3: Investment Strategy - Investors are encouraged to construct a strategy that includes the Hong Kong Innovative Drug ETF (513120), Medical ETF Leader (560260), and Pharmaceutical and Health ETF (159938) to capture opportunities across the entire innovative drug supply chain [1] - The three ETFs form a closed loop: the Hong Kong Innovative Drug ETF addresses R&D breakthroughs, the Medical ETF Leader focuses on industrialization, and the Pharmaceutical and Health ETF captures commercialization [2] Group 4: ETF Details - The Hong Kong Innovative Drug ETF (513120) tracks the China Securities Hong Kong Innovative Drug Index, with a current P/E ratio of 27 times and a valuation at the 18th percentile historically [4] - The Medical ETF Leader (560260) focuses on medical devices and services, with a P/E ratio of 31 times and a valuation at the 20th percentile historically [4] - The Pharmaceutical and Health ETF (159938) covers the pharmaceutical and health industry, with a P/E ratio of 35 times and a valuation at the 43rd percentile historically [4]